The First Choice of Botulinum Toxin Type A

Purified Botulinum Toxin Type A Complex

Neuronox®
The First Choice of Botulinum Toxin Type A

Proven Efficacy & Safety
The efficacy and safety of Neuronox® is proved and verified to be comparable to Botox (Allergan Inc.)’s in clinical studies.

Global Product
Global Product, Neuronox® has been sold in over 50 countries, since its first launch in 2004. Neuronox® is being sold worldwide under different brand names, such as Sias®, Cunox®, Botulift® and Meditoxin®.

Various choices
Neuronox® consists of 50, 100 and 200 units, offering various choices according to the application. It is easier to use for doctors and more economical for patients.
Proven Efficacy & Safety

The efficacy and the safety of Neuronox® are proved to be comparable to Botox(Allergan Inc.)’s in various clinical studies.

1. Glabellar Frown Lines

Comparative clinical study for glabellar frown lines\(^1\) with Neuronox® vs. Botox®: Comparable Efficacy and Safety

Methodology

Multicenter, double-blind, randomized, parallel design, active-controlled phase III clinical study. Each patient was randomly assigned to receive 20U (0.5ml) of either Neuronox®(n=142) or Botox® (n=146). The total dose was distributed over 5 injection points into corrugators and procerus. Results of the treatment were evaluated at 4-week intervals: up to 16 week.

Subjects

314 healthy adult patients (aged between 20 to 65) with moderate or severe glabellar lines at maximum frown. *four-point scale (0=none, 1=mild, 2=moderate, 3=severe)

Results

Neuronox® was proved its non-inferiority to Botox® in this clinical study. Therefore, Neuronox® is effective and safe for the treatment of glabellar frown lines.

SAFETY

In this study, 26.92% of patients treated with Neuronox® and 22.29% of patients received Botox® experienced adverse events. There was no statistical difference in the incidence and the severity of adverse events between two products (p=0.3416).

Comparative clinical study for glabellar frown lines with Neuronox® vs. Botox®: More satisfaction

1:1 clinical conversion ratio

* * * Glabellar lines improvement rate at maximum frown (PP set)

Patient satisfaction with the results (PP set)

1:1 clinical conversion ratio

* * * Patient satisfaction with the results (PP set)

BEFORE

AFTER

Photo taken at maximum frown before treatment with Neuronox® and after 14 days. Individual results may vary.
Proven Efficacy & Safety

The efficacy and the safety of Neuronox® are proved to be comparable to Botox (Allergan Inc.)’s in various clinical studies.

2. Essential Blepharospasm
Comparative clinical study for essential blepharospasm with Neuronox® vs. Botox®: Comparable Efficacy and Safety

Methodology
Multi-center, double blinded, randomized, active controlled, parallel designed, phase III clinical study

Subjects
60 patients diagnosed as essential blepharospasm (Neuronox® n=31 / Botox® n=29) with Neuronox® vs. Botox®: Comparable Efficacy and Safety

Results
The efficacy of Neuronox® was not inferior to Botox® in this clinical study. No difference was noted in the frequency of adverse event. Neuronox® can be safely used as an alternative to Botox® treatment at 1:1 equivalence.


3. Equinus Deformity in Cerebral Palsy
Comparative clinical study for equines deformity in cerebral palsy with Neuronox® vs. Botox®: Comparable Efficacy and Safety

Methodology
Multi-center, double blinded, randomized, active controlled, parallel designed, phase III clinical study

Subjects
119 pediatric patients diagnosed as spastic cerebral palsy with equinus foot deformity (Neuronox® n=60 / Botox® n=59) with Neuronox® vs. Botox®: Comparable Efficacy and Safety

Results
Neuronox® was not inferior to Botox® in this clinical study. No differences were noted in the frequency of adverse event. Neuronox® can be safely used as an alternative to Botox® treatment.

Global Product

Neuronox® is registered in 25 countries including Brazil, India, Hong Kong, and Lebanon, and is in the process of registration in other 30 countries.

Various Choice of products

Neuronox® offers various choices according to the application. It is easier to use for doctors and more economical for patients.

<table>
<thead>
<tr>
<th>Product</th>
<th>Neuronox® 50U</th>
<th>Neuronox® 100U</th>
<th>Neuronox® 200U</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Medytox Inc.</td>
<td>Same as left</td>
<td>Same as left</td>
</tr>
<tr>
<td>Drying Method</td>
<td>Freeze-dried</td>
<td>Same as left</td>
<td>Same as left</td>
</tr>
<tr>
<td>Potency per vial</td>
<td>50U</td>
<td>100U</td>
<td>200U</td>
</tr>
<tr>
<td>Composition</td>
<td>50 Units of Clostridium botulinum toxin type A complex</td>
<td>100 Units of Clostridium botulinum toxin type A complex</td>
<td>200 Units of Clostridium botulinum toxin type A complex</td>
</tr>
<tr>
<td>Diluent Added (0.9% sodium chloride)</td>
<td>Resulting Dose Units (Units /0.1mL)</td>
<td>Diluent Added (0.9% sodium chloride)</td>
<td>Resulting Dose Units (Units /0.1mL)</td>
</tr>
<tr>
<td>0.5mL</td>
<td>5.0U</td>
<td>0.5mL</td>
<td>5.0U</td>
</tr>
<tr>
<td>1.0mL</td>
<td>10.0U</td>
<td>1.0mL</td>
<td>10.0U</td>
</tr>
<tr>
<td>2.0mL</td>
<td>20.0U</td>
<td>2.0mL</td>
<td>20.0U</td>
</tr>
<tr>
<td>4.0mL</td>
<td>40.0U</td>
<td>4.0mL</td>
<td>40.0U</td>
</tr>
</tbody>
</table>
Neuronox®

The First Choice of Botulinum Toxin Type A

Purified Botulinum Toxin Type A Complex